Skip to main content
. 2019 Jan 4;11(1):44. doi: 10.3390/cancers11010044

Figure 2.

Figure 2

Comparison of erlotinib and phenformin activity on three different cell culture systems. (A) Schematic representation (upper panels) and 3D reconstructions of immunofluorescent images (lower panels) of cells stained for F-actin (red) and nuclei (DAPI, blue) of three cell culture systems: 2D growth on plastic plates (left images, 63× magnification); 3D scaffold growth using 3D-Alvetex system (middle images 63× magnification); and 3D neurospheres (right images, 63× magnification, zoom 2×). 2D plastic and 3D scaffolds were previously coated with diluted Matrigel as described in section Matrigel-coating for 2D growth. (B) Bar charts representing surviving fraction of cells relative to control grown on different culture systems. G7 and E2 patient-derived GBM cell lines treated with vehicle (DMSO, control), phenformin (10 µM), or erlotinib (1 µM). Drug-treated cells were normalised to vehicle (mean ± SD, of three independent experiments). * p < 0.05, relative to DMSO control of their respective culture system.